EDIT - Editas Medicine, Inc.
收市後：
| 前收市價 | 8.96 |
| 開市 | 8.96 |
| 買盤 | 0.00 x 1400 |
| 賣出價 | 0.00 x 3200 |
| 今日波幅 | 8.80 - 9.31 |
| 52 週波幅 | 6.33 - 19.97 |
| 成交量 | |
| 平均成交量 | 1,829,660 |
| 市值 | 633.38M |
| Beta 值 (5 年，每月) | 1.85 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -3.13 |
| 業績公佈日 | 2023年8月01日 - 2023年8月07日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 12.71 |
InvestorPlace7 Short-Squeeze Stocks Set for a May Rally
A practice designed for only the most daring traders, the best short-squeeze stocks to buy now could yield tremendous gains. To be sure, approaching this sector means staring at the possibility of severe losses in the face. Still, because of the extreme risks involved, the rewards could be massive. To understand why, when bulls invest in a company, the risk is always that the security can go to zero. However, no upside price ceiling theoretically exists. Therefore, when bears take the opposite-s
Insider MonkeyEditas Medicine, Inc. (NASDAQ:EDIT) Q1 2023 Earnings Call Transcript
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2023 Earnings Call Transcript May 5, 2023 Operator: Good morning, and welcome to Editas Medicine’s First Quarter Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the […]
InvestorPlaceThe 3 Most Promising Gene Editing Stocks to Buy in 2023
Gene editing stocks are one of the hottest sectors in medicine today. Genes are the foundation of life, and from creating new organisms to curing incurable diseases, the editing of genes can bring radical changes to life as we know it. That’s why CRISPR stocks that can edit genes have been in such demand both in research and in the biochemistry sector. But while gene editing can do many things, it can be hard to sort out science-fact from science-fiction. There are still many challenges that gen
Insider Monkey12 Gene Editing Stocks With the Best Long-Term Potential
In this article, we will take a look at the 12 gene editing stocks with the best long-term potential. To see more such companies, go directly to 5 Gene Editing Stocks With the Best Long-Term Potential. Gene editing stocks are gaining ground on the back of an upbeat tone in the industry, helped by a […]
Insider MonkeyTop 10 CRISPR Stocks To Buy
In this article, we discuss the top 10 CRISPR stocks to buy. If you want to see more stocks in this selection, check out Top 5 CRISPR Stocks To Buy. Molecular biology, genetics, and genomics are in a significant period in history where technical capabilities and methods enable the editing of specific DNA segments and […]
InvestorPlace7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
While it’s a common conspiracy theory – and comedic punchline – that medical innovators only seek to manage problems rather than cure them, the reality is that several biotech stocks to buy undergird myriad therapeutic advancements. For patients, they represent hope for a positive outcome. And for investors, they may enjoy life-changing profitability while putting their money down for good causes. According to Grand View Research, the global biotech market size reached an estimated valuation of
Insider Monkey11 Most Promising Gene Editing Stocks According to Analysts
In this article, we will take a look at the 11 most promising gene editing stocks according to analysts. To see more such companies, go directly to 5 Most Promising Gene Editing Stocks According to Analysts. Genetics is one of the most promising areas where companies are pouring billions of dollars in R&D to find […]
Insider MonkeyEditas Medicine, Inc. (NASDAQ:EDIT) Q4 2022 Earnings Call Transcript
Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2022 Earnings Call Transcript February 22, 2023 Operator: Good morning and welcome to Editas Medicine’s Fourth Quarter and Full-year 2022 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being […]
InvestorPlace3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later
CRISPR is an acronym which refers to a series of DNA sequences in bacteria and other organisms. Scientists have begun editing genes, including CRISPR, to try to improve human health. Using CRISPR, scientists can slice into DNA, altering it and reducing the negative impact of a variety of maladies. CRISPR-based medicines and therapies are currently being tested as treatments for cancer, neurodegenerative diseases, and other illnesses. CRISPR has come a long way in a short time. An initial paper d
BenzingaAnalyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
Cantor Fitzgerald initiated coverage on Editas Medicine Inc (NASDAQ: EDIT) with an Overweight rating and a price target of $15. The analyst says that following the recent pipeline reprioritization and pausing of internal investments in the retinal disease/induced pluripotent stem cell-derived natural killer cell programs, Editas shares are well-positioned to appreciate in the coming year due to favorable IP positioning and expected clinical data updates. Also See: Citing Small Population, Editas
InvestorPlace7 CRISPR Stocks With the Best Long-Term Potential
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis. As a result, companies developing CRISPR-based products and services have seen significant valuation growth since inception, with many CRISPR stocks having excellent long-term upside potential in this regard. Several companies at the forefront of CRISPR technology have seen their stocks
BenzingaShoreline Biosciences Acquires Editas' iNK Cell Franchise, Related Gene Editing Technologies
Editas Medicine Inc (NASDAQ: EDIT) has agreed to license its proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) and AsCas12a gene editing technologies to Shoreline Biosciences. Shoreline will also acquire Editas Medicine's preclinical gene-edited induced pluripotent stem cell (iPSC) derived natural killer cell (iNK) programs and manufacturing technologies. Shoreline will pay Editas Medicine an undisclosed upfront payment at the close of the transaction. Editas Medicine is eligible to
InvestorPlace3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
CRISPR could revolutionize the way we treat thousands of diseases. Many of these diseases occur when mutations affect genes, or when people have the wrong amount of genetic material, the Cleveland Clinic reported. Fortunately, CRISPR, or clustered regularly interspaced short palindromic repeats, has the potential to treat most, if not all of these illnesses. In fact, according to Interesting Engineering, “researchers have already identified DNA errors as the cause of nearly 7,000 diseases. Thank
BenzingaEditas Medicine Touts Positive Safety, Efficacy Data From Two Sickle Cell Disease Patients
Editas Medicine Inc (NASDAQ: EDIT) announced initial clinical data from the first two sickle cell disease (SCD) patients treated with EDIT-301 in the Phase 1/2 RUBY trial. EDIT-301 is under development for the treatment of severe sickle cell disease. The clinical data includes safety data from the first two patients and efficacy data from the first patient treated. Both treated patients demonstrated successful neutrophil and platelet engraftment. Additionally, neither patient has experienced any
BenzingaGene Editing Stock's Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatment
Credit Suisse has downgraded Editas Medicine Inc (NASDAQ: EDIT) from Outperform to Neutral with a price target of $13 from $25. Thursday, Editas announced clinical data from the Phase 1/2 BRILLIANCE trial of EDIT-101, an in vivo CRISPR/Cas9 genome editing medicine. Given the small population (around 300 in the U.S.), the company will pause enrollment in the BRILLIANCE trial and seek to identify a collaboration partner to continue the development of EDIT-101. Credit Suisse says that Editas still
BenzingaCiting Small Population, Editas Medicine Pauses Work On Gene Therapy Trial For Genetic Eye Disorder
Editas Medicine Inc (NASDAQ: EDIT) announced clinical data from the Phase 1/2 BRILLIANCE trial of EDIT-101, an in vivo CRISPR/Cas9 genome editing medicine. EDIT-101 is under development for the treatment of blindness due to Leber congenital amaurosis 10 (LCA10, a CEP290-related retinal degenerative disorder). It is designed to repair the IVS26 CEP290 mutant allele that impacts approximately 1,500 LCA10 patients in the U.S. The BRILLIANCE update includes safety and efficacy data from all 14 patie
Insider Monkey10 Most Promising Gene Therapy Companies to Watch
In this piece, we will take a look at the ten most promising gene therapy companies to watch. For more companies, take a look at 5 Most Promising Gene Therapy Companies to Watch. Gene therapy is a revolutionary new technology that has followed the growing advances in computing power. The human body is estimated to […]
- Insider Monkey
10 Best Gene Editing Stocks To Buy
In this article, we discuss 10 best gene editing stocks to buy. If you want to see more stocks in this selection, check out 5 Best Gene Editing Stocks To Buy. A report by The Wall Street Journal dated September 16 suggests that Intellia Therapeutics, Inc. (NASDAQ:NTLA) revealed positive early-stage trial results for its CRISPR […]